Wave Life Sciences/$WVE
1D1W1MYTD1Y5YMAX
Capital at risk
About Wave Life Sciences
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
- Ticker
- $WVE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 317
- Headquarters
- Cambridge, United States
- Website
- wavelifesciences.com
WVE Metrics
BasicAdvanced
$888M
-
-$1.08
-1.29
-
Price and volume
Market cap
$888M
Beta
-1.29
52-week high
$5.53
52-week low
$4.40
Financial strength
Current ratio
9.987
Quick ratio
9.672
Long term debt to equity
0.088
Total debt to equity
0.096
Profitability
EBITDA (TTM)
-214.52
Gross margin (TTM)
-202.00%
Net profit margin (TTM)
-309.73%
Operating margin (TTM)
-333.36%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-33.60%
Return on equity (TTM)
-67.42%
Valuation
Price to revenue (TTM)
12.96
Price to book
1.92
Price to tangible book (TTM)
1.92
Price to free cash flow (TTM)
-4.387
Free cash flow yield (TTM)
-22.80%
Free cash flow per share (TTM)
-1.027
Growth
Revenue change (TTM)
-30.42%
Earnings per share change (TTM)
28.66%
3-year revenue growth (CAGR)
21.38%
10-year revenue growth (CAGR)
65.78%
3-year earnings per share growth (CAGR)
-6.70%
10-year earnings per share growth (CAGR)
-5.16%
Bulls say / Bears say
WVE-007 produced encouraging Phase 1 interim data, including clinically meaningful reductions in visceral fat and waist circumference with preservation of lean mass six months after a single dose. The company has now initiated the Phase 2a portion of INLIGHT, supporting a potentially differentiated, infrequent-dosing obesity profile. (Wave Life Sciences INLIGHT update)
WVE-006 showed a potentially differentiated RNA-editing profile in alpha-1 antitrypsin deficiency, achieving an MZ-like phenotype across biweekly and monthly dosing regimens. Wave also reported that its data support discussions with the FDA regarding a potential accelerated-approval pathway. (Wave Life Sciences Q2 2026 results)
Wave had $490.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026, with management projecting funding into the third quarter of 2028. That balance sheet provides time to advance WVE-007, WVE-006, WVE-008, and additional RNA-medicine programs without an immediate financing requirement. (Wave Life Sciences Q2 2026 results)
Wave remains a clinical-stage biotech with minimal revenue and substantial losses: Q2 2026 revenue was $2.3 million versus a $69.4 million net loss, while R&D and G&A expenses continued rising. Continued cash burn creates eventual financing and dilution risk despite the current runway. (Wave Life Sciences Q2 2026 results)
WVE-007’s obesity evidence is still early-stage: the program is transitioning from Phase 1 into Phase 2a, and efficacy, durability, and safety in people with higher BMI and comorbidities remain unvalidated. The investment case therefore depends heavily on forthcoming clinical data rather than established efficacy. (ClinicalTrials.gov)
Several major value drivers remain exposed to execution and regulatory risk. WVE-006’s potential accelerated-approval route depends on future FDA discussions and data, while WVE-008 was only expected to reach the clinical-trial application stage in the second half of 2026. (Wave Life Sciences Q2 2026 results)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Upcoming events
No upcoming events
Funds containing WVE
AllUSDGBPEUR
Fund name | Fund size | $WVE weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.